Latanoprost: Technical Guidance for Research Applications

What This Product Solves

Latanoprost, a prostaglandin F2α analogue, is primarily used in research settings to model and investigate mechanisms of intraocular pressure (IOP) regulation, particularly in the context of glaucoma and ocular hypertension. Its established role as an FP prostaglandin receptor agonist allows for the study of aqueous humor outflow modulation and related pharmacodynamics. The compound is supplied at ≥99.8% purity, verified by HPLC and NMR, making it suitable for experiments demanding high analytical confidence. Researchers rely on Latanoprost for in vitro and ex vivo studies focused on intraocular pressure reduction mechanisms and pharmacological modulation of the uveoscleral pathway. This product is not validated for use in diagnostics or clinical interventions and should not be used outside of approved laboratory protocols. [source_type: product_spec | source_link: https://www.apexbt.com/latanoprost.html]

Protocol Parameters

• assay: Compound solubility assessment | value_with_unit: ≥43.3 mg/mL in DMSO, ≥10.12 mg/mL in water (ultrasonication), ≥45.5 mg/mL in ethanol | applicability: Preparation of stock solutions for cell-based and biochemical assays | rationale: Ensures accurate dosing and reproducibility by confirming solubility in common laboratory solvents | source_type: product_spec [source_link: https://www.apexbt.com/latanoprost.html]
• assay: Storage temperature for stability | value_with_unit: -20°C | applicability: Long-term compound preservation for repeated or extended studies | rationale: Low temperatures minimize degradation and maintain compound integrity; avoid repeated freeze-thaw cycles | source_type: product_spec [source_link: https://www.apexbt.com/latanoprost.html]
• assay: Solution shelf-life | value_with_unit: Use freshly prepared; avoid long-term storage | applicability: Ensures experimental consistency and minimizes breakdown of active compound | rationale: Latanoprost solutions are prone to hydrolysis and degradation over time, compromising data quality | source_type: product_spec [source_link: https://www.apexbt.com/latanoprost.html]
• assay: Typical working concentration range | value_with_unit: 0.01–10 μM (workflow recommendation) | applicability: Cell-based and tissue assays probing aqueous humor outflow or IOP regulation | rationale: Provides a starting point for titration to optimize signal-to-noise in custom assay formats | source_type: workflow_recommendation

Workflow Setup and QC Checklist

1. Confirm receipt of Latanoprost with a certificate of analysis indicating ≥99.8% purity via HPLC and NMR.
2. Allow compound to equilibrate to room temperature before opening to prevent condensation.
3. Prepare stock solutions in DMSO, ethanol, or water (with ultrasonic assistance for water). Use glass vials to avoid plasticizer contamination.
4. Filter sterilize solutions if required for cell culture.
5. Aliquot stocks to minimize freeze-thaw cycles and store at -20°C.
6. Prepare fresh working dilutions immediately prior to use; avoid storing diluted solutions for more than a single experimental day.
7. Include vehicle-only controls (DMSO, ethanol, or water) in all experiments to rule out solvent effects.
8. Document lot number, preparation date, and storage conditions with each experimental batch for traceability.

Common Failure Modes and Fixes

• Precipitation upon dilution: If Latanoprost precipitates when diluted into aqueous buffers, verify that the stock solution concentration does not exceed the compound’s solubility limit. Use ultrasonic assistance for water-based dilutions. If precipitation persists, switch to DMSO or ethanol as a primary solvent and dilute into buffer with rapid mixing.
• Loss of activity: Degradation can occur if solutions are stored at room temperature or exposed to light. Always prepare fresh working solutions and store protected from light at -20°C. Discard any solution that changes color or shows particulate matter.
• Variable assay results: Inadequate mixing or incomplete dissolution can cause inconsistent dosing. Vortex and, if necessary, briefly sonicate solutions. Confirm compound is completely dissolved before application.
• Solvent toxicity to cells: Ensure final solvent concentration in cell assays does not exceed 0.1–0.5% (workflow recommendation). Always include solvent controls to distinguish compound-specific effects from vehicle artifacts.

Scope and Limitations

Latanoprost from APExBIO is intended solely for laboratory-based research on glaucoma, ocular hypertension, and aqueous humor outflow modulation. Its formulation and purity specifications support controlled experiments on FP prostaglandin receptor signaling and intraocular pressure reduction. The compound should not be used for any in vivo studies involving humans or animals unless specifically approved by institutional review boards and within the regulatory framework. No clinical, diagnostic, or therapeutic claims are supported based on the supplied specifications. Experimental outcomes may vary depending on cell lines, tissue types, and assay conditions; researchers should perform pilot studies to optimize protocols. When solution stability or solubility is a concern, alternative prostaglandin analogues may be considered, but such substitutions should be validated independently. [source_type: product_spec | workflow_recommendation]

Conclusion

Latanoprost (SKU B3411) provides a rigorously characterized prostaglandin F2α analogue suitable for studies of ocular pharmacology, especially those investigating mechanisms of intraocular pressure modulation and glaucoma progression. By adhering to established solubility, storage, and preparation guidelines, researchers can maximize the reliability of their results. For further details, consult the Latanoprost product page on APExBIO. Always operate within the product’s intended research-only scope and document workflow parameters for reproducibility.